Abstract

Objective: Small for gestational age (SGA) is a heterogeneous condition influenced by fetal, placental, maternal, and genetic factors. While most SGA children experience catch-up growth within the first two years, up to 10-15%  remain short-statured and may require growth hormone (GH) therapy. This study evaluated the clinical characteristics, genetic factors, and responses to recombinant GH (rGH) therapy in non-syndromic SGA children with persistent short stature.

Material and Methods: We retrospectively analyzed 36 non-syndromic short-statured children born SGA who were evaluated in a tertiary center. Genetic testing, including karyotyping and microarray analysis for copy number variations (CNVs), was performed. Growth response to rGH therapy was assessed in 19 patients over a three-year period.

Results: Among the 19 patients receiving rGH therapy, the mean height SDS improved from -3.04±0.58 at baseline to -2.07±0.67 after three years, with an average gain of 0.97 SDS. CNVs were identified in 6 patients (16.66%), with several pathogenic or likely pathogenic variants, including deletions and duplications in regions associated with growth and developmental disorders.

Conclusion: A significant proportion of non-syndromic SGA children with persistent short stature exhibit CNVs, underscoring the genetic complexity of this condition. rGH therapy effectively improves growth outcomes, but individual responses vary. These findings highlight the need for routine genetic screening and personalized treatment strategies to optimize care for SGA children.

Keywords: Copy number variations (CNVs), Small for gestational age, Short stature, Recombinant growth hormone (rGH)

References

  1. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the Child Born Small for Gestational Age through to Adulthood: A Consensus Statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92(3):804-10. https://doi.org/10.1210/jc.2006-2017
  2. de Onis M, Habicht JP. Anthropometric reference data for international use: recommendations from a World Health Organization Expert Committee. Am J Clin Nutr 1996;64(4):650-8.
  3. Schlaudecker EP, Munoz FM, Bardají A, Boghossian NS, Khalil A, Mousa H, et al. Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Vaccine. 2017;35(48 Pt A):6518-28. https://doi.org/10.1016/j.vaccine.2017.01.040
  4. Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL. Children born small for gestational age: do they catch up? Pediatr Res. 1995;38(2):267-71. https://doi.org/10.1203/00006450-199508000-00022
  5. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92(3):804-10. https://doi.org/10.1210/jc.2006-2017
  6. Saenger P, Reiter E. Genetic factors associated with small for gestational age birth and the use of human growth hormone in treating the disorder. Int J Pediatr Endocrinol. 2012;2012(1):12. https://doi.org/10.1186/1687-9856-2012-12
  7. Finken MJJ, van der Steen M, Smeets CCJ, Walenkamp MJE, de Bruin C, Hokken-Koelega ACS, et al. Children Born Small for Gestational Age: Differential Diagnosis, Molecular Genetic Evaluation, and Implications. Endocr Rev. 2018;39(6):851-94. https://doi.org/10.1210/er.2018-00083
  8. Martín-Calvo N, Goni L, Tur JA, Martínez JA. Low birth weight and small for gestational age are associated with complications of childhood and adolescence obesity: Systematic review and meta-analysis. Obes Rev. 2022;23 Suppl 1:e13380. https://doi.org/10.1111/obr.13380
  9. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. Pediatrics. 2003;111(6 Pt 1):1253-61. https://doi.org/10.1542/peds.111.6.1253
  10. Ferrigno R, Savage MO, Cioffi D, Pellino V, Savanelli MC, Klain A. Effects of long-term treatment with recombinant growth hormone on growth outcome in children born small for gestational age: a systematic review. Rev Endocr Metab Disord. 2025;26(2):147-59. https://doi.org/10.1007/s11154-024-09911-y
  11. Danowitz M, Grimberg A. Clinical Indications for Growth Hormone Therapy. Adv Pediatr. 2022;69(1):203-17. https://doi.org/10.1016/j.yapd.2022.03.005
  12. Maiorana A, Cianfarani S. Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics. 2009;124(3):e519-31. https://doi.org/10.1542/peds.2009-0293
  13. Arroyo-Ruiz R, Urbano-Ruiz C, García-Berrocal MB, Marcos-Vadillo E, Isidoro-García M, Martín-Alonso MM, et al. Clinical and Genetic Characterization of a Cohort of Small-for-Gestational-Age Patients: Cost-Effectiveness of Whole-Exome Sequencing and Effectiveness of Treatment with GH. J Clin Med. 2024;13(14):4006. https://doi.org/10.3390/jcm13144006
  14. Giacomozzi C. Genetic Screening for Growth Hormone Therapy in Children Small for Gestational Age: So Much to Consider, Still Much to Discover. Front Endocrinol (Lausanne). 2021;12:671361. https://doi.org/10.3389/fendo.2021.671361
  15. Campos-Martorell A, Fernández-Cancio M, Clemente León M, Mogas Viñals E, Fàbregas Martori A, Carrascosa Lezcano A, et al. Seventy eight children born small for gestational age without catch-up growth treated with growth hormone from the prepubertal stage until adult height age. An evaluation of puberty and changes in the metabolic profile. Endocrinol Diabetes Nutr (Engl Ed). 2021;68(9):612-20. https://doi.org/10.1016/j.endinu.2021.01.009
  16. de Bruin C, Dauber A. Growth Hormone Therapy in the Short SGA Child: Does Time Matter? J Clin Endocrinol Metab. 2023;108(7):e495-e6. https://doi.org/10.1210/clinem/dgad021
  17. Jensen RB, Thankamony A, O’Connell SM, Kirk J, Donaldson M, Ivarsson SA, et al. A randomised controlled trial evaluating IGF1 titration in contrast to current GH dosing strategies in children born small for gestational age: the North European Small-for-Gestational-Age Study. Eur J Endocrinol. 2014;171(4):509-18. https://doi.org/10.1530/EJE-14-0419
  18. van Duyvenvoorde HA, Lui JC, Kant SG, Oostdijk W, Gijsbers AC, Hoffer MJ, et al. Copy number variants in patients with short stature. Eur J Hum Genet. 2014;22(5):602-9. https://doi.org/10.1038/ejhg.2013.203
  19. Zahnleiter D, Uebe S, Ekici AB, Hoyer J, Wiesener A, Wieczorek D, et al. Rare copy number variants are a common cause of short stature. PLoS Genet. 2013;9(3):e1003365. https://doi.org/10.1371/journal.pgen.1003365
  20. Canton AP, Costa SS, Rodrigues TC, Bertola DR, Malaquias AC, Correa FA, et al. Genome-wide screening of copy number variants in children born small for gestational age reveals several candidate genes involved in growth pathways. Eur J Endocrinol. 2014;171(2):253-62. https://doi.org/10.1530/EJE-14-0232
  21. Homma TK, Krepischi ACV, Furuya TK, Honjo RS, Malaquias AC, Bertola DR, et al. Recurrent Copy Number Variants Associated with Syndromic Short Stature of Unknown Cause. Horm Res Paediatr. 2018;89(1):13-21. https://doi.org/10.1159/000481777
  22. Shepherdson JL, Zheng H, Amarillo IE, McAlinden A, Shinawi M. Delineation of the 1q24.3 microdeletion syndrome provides further evidence for the potential role of non-coding RNAs in regulating the skeletal phenotype. Bone. 2021;142:115705. https://doi.org/10.1016/j.bone.2020.115705
  23. Miceli M, Failla P, Saccuzzo L, Galesi O, Amata S, Romano C, et al. Trait - driven analysis of the 2p15p16.1 microdeletion syndrome suggests a complex pattern of interactions between candidate genes. Genes Genomics. 2023;45(4):491-505. https://doi.org/10.1007/s13258-023-01369-7
  24. Boczek NJ, Lahner CA, Nguyen TM, Ferber MJ, Hasadsri L, Thorland EC, et al. Developmental delay and failure to thrive associated with a loss-of-function variant in WHSC1 (NSD2). Am J Med Genet A. 2018;176(12):2798-802. https://doi.org/10.1002/ajmg.a.40498
  25. Tan L, Bi B, Zhao P, Cai X, Wan C, Shao J, et al. Severe congenital microcephaly with 16p13.11 microdeletion combined with NDE1 mutation, a case report and literature review. BMC Med Genet. 2017;18(1):141. https://doi.org/10.1186/s12881-017-0501-9
  26. Toni L, Plachy L, Dusatkova P, Amaratunga SA, Elblova L, Sumnik Z, et al. The Genetic Landscape of Children Born Small for Gestational Age with Persistent Short Stature. Horm Res Paediatr. 2024;97(1):40-52. https://doi.org/10.1159/000530521
  27. Freire BL, Homma TK, Funari MFA, Lerario AM, Vasques GA, Malaquias AC, et al. Multigene Sequencing Analysis of Children Born Small for Gestational Age With Isolated Short Stature. J Clin Endocrinol Metab. 2019;104(6):2023-30. https://doi.org/10.1210/jc.2018-01971

Copyright and license

Copyright © 2025 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Özer E, Kılıç E, Kocaay P, Tepe D, Kılınç Uğurlu A, Büyükyılmaz G, et al. Growth response and genetic factors in SGA children: a study on rGH therapy and copy number variations. Turk J Pediatr Dis [Internet]. 2025 Jul. 2 [cited 2025 Jul. 7];:1-6. Available from: https://turkjpediatrdis.org/article/view/1118